Loading...

PE anti-mouse IFN-γ Antibody

Pricing & Availability
Clone
XMG1.2 (See other available formats)
Regulatory Status
RUO
Other Names
Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF)
Isotype
Rat IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
XMG1.2
PMA/Ionomycin-stimulated BALB/c T-cells were stained with CD3 FITC and XMG1.2 PE
  • XMG1.2
    PMA/Ionomycin-stimulated BALB/c T-cells were stained with CD3 FITC and XMG1.2 PE
Compare all formats See PE spectral data
Cat # Size Price Save
505807 25 µg ¥8,580
505808 100 µg ¥20,700
Description

IFN-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
E. coli-expressed, recombinant mouse IFN-γ
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The IFN-γ antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

ELISA1-4,11,14 or ELISPOT5 Detection: The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody (Cat. No. 505702/505706) as the capture antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard.
ELISA or ELISPOT Capture: The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with biotinylated R4-6A2 antibody (Cat. No. 505704) as the detection antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture (Cat. No. 505812).
Flow Cytometry7,8,12,13,16: The fluorochrome-labeled XMG1.2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ-producing cells within mixed cell populations.
Neutralization1-3,9,10: The XMG1.2 antibody can neutralize the bioactivity of natural or recombinant IFN-γ. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IFN-γ bioactivity in vivo and in vitro (Cat. No. 505812). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 505834) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of frozen tissue sections6,22,23, and immunocytochemistry.
Note: For testing mouse IFN-γ in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430801 to 430806) are specially developed and recommended.

Application References

(PubMed link indicates BioLegend citation)
  1. Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA, Neut)
  2. Sander B, et al. 1993. J. Immunol. Meth. 166:201. (ELISA, Neut)
  3. Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20. (ELISA, Neut)
  4. Yang X, et al. 1993. J. Immunoassay 14:129. (ELISA)
  5. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.19. (ELISPOT)
  6. Sander B, et al. 1991. Immunol. Rev. 119:65. (IHC)
  7. Ferrick D, et al. 1995. Nature 373:255. (FC)
  8. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  9. Peterson KE, et al. 2000. J. Virol. 74:5363. (Neut)
  10. DeKrey GK, et al. 1998. Infect. Immun. 66:827. (Neut)
  11. Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA)
  12. Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC)
  13. Lee JW, et al. 2006. Nature Immunol. 8:181. (FC) PubMed
  14. Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed
  15. Montfort M, et al.2004. J. Immunol. 173:4084. PubMed
  16. Haring JS, et al. 2008. J. Immunol. 180:2855. (FC) PubMed
  17. Jordan JM, et al. 2008. Infect Immun. 76:3717. PubMed
  18. Tonkin DR, et al. 2008. J. Immunol. 181:4516. PubMed
  19. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  20. Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (FC) PubMed
  21. Mykkanen OT, et al. 2014. PLoS One. 9:114790. PubMed
  22. Yokogawa M, et al. 2013. Mol. Carcinog. 52:760. (IHC)
  23. Mottram PL, et al. 1998. J Immunol. 161:602. (IHC)
Product Citations
  1. Chen R, et al. 2022. J Mol Cell Biol. 14:. PubMed
  2. Cheng C, et al. 2022. Cell Mol Gastroenterol Hepatol. 15:261. PubMed
  3. Pan Y, et al. 2023. Adv Sci (Weinh). 10:e2206792. PubMed
  4. Wang X, et al. 2023. J Immunother Cancer. 11:. PubMed
  5. Lu C, et al. 2023. Antiviral Res. 212:105556. PubMed
  6. Zhuang WR, et al. 2023. Nat Commun. 14:1675. PubMed
  7. Tan X, et al. 2023. Adv Sci (Weinh). 10:e2206768. PubMed
  8. Martins Nascentes Melo L, et al. 2023. J Immunother Cancer. 11:. PubMed
  9. Li D, et al. 2023. Ann Med. 55:2189295. PubMed
  10. Zuo B, et al. 2023. Clin Transl Oncol. . PubMed
  11. Pandit M, et al. 2023. Nat Commun. 14:2593. PubMed
  12. Yu L, et al. 2023. Front Oncol. 13:1174713. PubMed
  13. Deng G, et al. 2023. Cancers (Basel). 15:. PubMed
  14. Wang Y, et al. 2023. iScience. 26:106630. PubMed
  15. Gao Y, et al. 2023. iScience. 26:106729. PubMed
  16. Vereertbrugghen A, et al. 2023. J Neuroinflammation. 20:120. PubMed
  17. Changsheng H, et al. 2023. Sci Adv. 9:eade4186. PubMed
  18. Yang QC, et al. 2023. iScience. 26:106916. PubMed
  19. Sandu I, et al. 2020. Nat Commun. 11:4454. PubMed
  20. Wang HH, et al. 2022. J Biomed Sci. 29:36. PubMed
  21. Miki H, et al. 2020. J Immunol. 204:1892. PubMed
  22. Zhang H, et al. 2022. Eur J Immunol. 52:978. PubMed
  23. Jia JJ, et al. 2022. J Leukoc Biol. 112:157. PubMed
  24. Chakraborty P, et al. 2022. Cancer Res. 82:1969. PubMed
  25. Lu R, et al. 2022. Scand J Immunol. 96:e13177. PubMed
  26. Tu J, et al. 2022. Cancer Sci. 113:2496. PubMed
  27. Liu H, et al. 2022. Cell Rep Med. 3:100660. PubMed
  28. Backlund C, et al. 2022. Proc Natl Acad Sci U S A. 119:e2204078119. PubMed
  29. Kang IH, et al. 2022. iScience. 25:104818. PubMed
  30. Wei M, et al. 2022. Front Immunol. 13:1017574. PubMed
  31. Xu H, et al. 2022. Aging Dis. 13:1875. PubMed
  32. Tan TCJ, et al. 2022. Nat Commun. 13:7796. PubMed
  33. Wang Z, et al. 2022. Cell Rep. 41:111890. PubMed
  34. Chan L, et al. 2022. Cells. 12: . PubMed
  35. Liu H, et al. 2023. Cell Death Differ. :. PubMed
  36. Mandour MF, et al. 2023. Front Med (Lausanne). 9:1057252. PubMed
  37. Kuehm LM, et al. 2021. Cancer Immunol Res. 9:227. PubMed
  38. Khojandi N, et al. 2021. Cancer Immunol Res. 9:214. PubMed
  39. Wight AE, et al. 2022. Proc Natl Acad Sci U S A. 119:e2200757119. PubMed
  40. Wu MJ, et al. 2022. Cancer Discov. 12:812. PubMed
  41. Tan L, et al. 2022. Aging Dis. 13:1562. PubMed
  42. Wang H, et al. 2013. J Immunol. 191:6010. PubMed
  43. Kim K, et al. 2016. PLoS One. 11: 0148576. PubMed
  44. Liu Y, et al. 2021. Cell Metabolism. 33(6):1221-1233.e11. PubMed
  45. Chen Y, et al. 2020. Virol Sin. . PubMed
  46. Bradley CP et al. 2017. Cell host & microbe. 22(5):697-704 . PubMed
  47. Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed
  48. Toubai T, et al. 2017. Blood Adv. 1.095138889. PubMed
  49. Yu X, et al. 2020. Nat Commun. 11:1110. PubMed
  50. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  51. Zhou J, et al. 2021. Int J Med Sci. 18:3516. PubMed
  52. Kim D, et al. 2021. Nanomicro Lett. 13:31. PubMed
  53. Gern BH, et al. 2021. Cell Host Microbe. 29(4):594-606.e6. PubMed
  54. Lin W, et al. 2020. Theranostics. 10:4871. PubMed
  55. Zhou J, et al. 2019. Immunity. 50:403. PubMed
  56. Shi L, et al. 2019. Theranostics. 9:4115. PubMed
  57. Alissafi T, et al. 2018. J Clin Invest. 128:3840. PubMed
  58. Yang F, et al. 2021. Front Microbiol. 11:512581. PubMed
  59. Kiritsy MC, et al. 2021. Elife. 10:. PubMed
  60. Stegelmeier AA, et al. 2022. Biomedicines. 10:. PubMed
  61. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  62. Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed
  63. Coleby R, et al. 2021. Clin Exp Rheumatol. :39. PubMed
  64. Zhang S, et al. 2022. Cell Death Dis. 13:844. PubMed
  65. Xia S, et al. 2014. J Leukoc Biol. 95:733. PubMed
  66. Su N, Xiong Y 2016. Sci Rep. 6:22658. PubMed
  67. Dong L, et al. 2021. Cancer Cell. . PubMed
  68. Gálvez-Cancino F, et al. 2017. Vaccine. 10.1016/j.vaccine.2017.06.041. PubMed
  69. Wang X, et al. 2018. Int Immunopharmacol. 56:249. PubMed
  70. Liu QZ, et al. 2018. Front Immunol. 1.131944444. PubMed
  71. Mayer RL, et al. 2022. Nat Commun. 13:6075. PubMed
  72. Snyder LM, et al. 2021. PLoS Pathog. 17:e1009970. PubMed
  73. Nagatake T, et al. 2022. Mucosal Immunol. 15:289. PubMed
  74. Herman JD, et al. 2021. Nat Commun. 12:6853. PubMed
  75. Galeano Niño JL, et al. 2020. J Cell Sci. . PubMed
  76. Saito S, et al. 2020. Nutrients. 12:. PubMed
  77. Tang Y, et al. 2020. Front Immunol. 11:585918. PubMed
  78. Chakrabarti J, et al. 2018. Oncotarget. 9:37439. PubMed
  79. Oyarce C, et al. 2018. Front Immunol. 8:1794. PubMed
  80. Papafragkos I, et al. 2022. Front Immunol. 13:889075. PubMed
  81. Xiong A, et al. 2022. EBioMedicine. 83:104239. PubMed
  82. Koenecke C, et al. 2012. J Immunol. 189:2890. PubMed
  83. Michel M, et al. 2012. Proc Natl Acad Sci U S A. 109:17459. PubMed
  84. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  85. Chen D, et al. 2018. Nat Commun. 9:873. PubMed
  86. Dai B, et al. 2022. Theranostics. 12:7603. PubMed
  87. Kuttke M, et al. 2022. Front Immunol. 13:695576. PubMed
  88. Xu X, et al. 2021. J Nanobiotechnology. 19:376. PubMed
  89. Subbiah J, et al. 2022. NPJ Vaccines. 7:68. PubMed
  90. Wang C, et al. 2021. Cell Rep. 37:110021. PubMed
  91. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
  92. Alissafi T, et al. 2020. Cell Metabolism. 32(4):591-604.e7. PubMed
  93. Sharma S, et al. 2015. J Immunol. 194:5529. PubMed
  94. Pan W et al. 2017. Immunity. 47(2):284-297 . PubMed
  95. Ning X, et al. 2019. Mol Cell. 74:19. PubMed
  96. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  97. An J, et al. 2022. iScience. 25:103570. PubMed
  98. Han JP, et al. 2022. Sci Adv. 8:eabj6901. PubMed
  99. Yu Y, et al. 2022. Nat Commun. 13:6357. PubMed
  100. Wan Y, et al. 2014. Vaccine. 41:241. PubMed
  101. Sandrock I, et al. 2015. PLoS One. 10: 0145010. PubMed
  102. Koren N, et al. 2021. Cell Host Microbe. 29(2):197-209.e5. PubMed
  103. Uchil PD et al. 2018. Cell host & microbe. 25(1):87-100 . PubMed
  104. Probst P, et al. 2017. Cancer Res. 77:3644. PubMed
  105. Caronni N, et al. 2018. Cancer Res. 78:1685. PubMed
  106. Srey MT, et al. 2020. PLoS Negl Trop Dis. 14:e0008842. PubMed
  107. Chen D, et al. 2022. J Neuroinflammation. 19:112. PubMed
  108. Cha SE, et al. 2021. Oncoimmunology. 10:1899469. PubMed
  109. Canton J, et al. 2021. Nat Immunol. 22:140. PubMed
  110. Shami A, et al. 2015. Sci Rep. 5: 13904. PubMed
  111. Gungor B, et al. 2014. Sci Transl Med. 6:235. PubMed
  112. Hegde S, et al. 2020. Cancer Cell. 37(3):289-307. PubMed
  113. Duan RN, et al. 2021. J Neuroinflammation. 18:145. PubMed
  114. Hanasoge Somasundara AV, et al. 2021. Cell Rep. 37:110099. PubMed
  115. Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed
  116. Cho K, Hill A 2008. J Immunol Methods. 330:137. PubMed
  117. Condotta S, et al. 2015. J Immunol. 195: 116 - 125. PubMed
  118. Satoh M, et al. 2016. Sci Rep. 6:28473. PubMed
  119. Gong Y, et al. 2020. Cell Metabolism. 33(1):51-64.e9. PubMed
  120. Espinosa JR, et al. 2018. Front Immunol. 9:1371. PubMed
  121. Hundt M, et al. 2009. J Immunol. 183:1685. PubMed
  122. Reese B, et al. 2020. J Immunol. 205:3218. PubMed
  123. Brigas HC, et al. 2021. Cell Reports. 36(9):109574. PubMed
  124. Sartorius R, et al. 2015. EMBO Mol Med. 7: 973 - 988. PubMed
  125. Mirando AC, et al. 2020. Oncoimmunology. 9:1760685. PubMed
  126. Garo LP, et al. 2019. Cell Rep. 28:3353. PubMed
  127. Li W, et al. 2019. Nat Commun. 10:3349. PubMed
  128. Yan Y, et al. 2018. JCI Insight. 3. PubMed
  129. Place D, et al. 2017. PLoS One. 10.1371/journal.pone.0190384. PubMed
  130. Palazon A, et al. 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. PubMed
  131. Bosnjak B, et al. 2021. Front Immunol. 12:772240. PubMed
  132. Tian X, et al. 2022. J Cell Mol Med. 26:693. PubMed
  133. Ma Y, et al. 2013. J Immunol. 190:5588. PubMed
  134. Dutow P, et al. 2014. J Infect Dis. 209:1269. PubMed
  135. QT N, et al. 2015. Antimicrob Agents Chemother. 59: 6308-6316. PubMed
  136. Latasa C, et al. 2016. PLoS One. 11: 0161216. PubMed
  137. Holokai L, et al. 2020. Cancers (Basel). 12:00. PubMed
  138. Galeano Niño JL, et al. 2020. J Cell Sci. 133:00:00. PubMed
  139. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  140. Marcus A et al. 2018. Immunity. 49(4):754-763 . PubMed
  141. Yang Z, et al. 2021. Onco Targets Ther. 14:4239. PubMed
  142. De Ponte Conti B, et al. 2021. Elife. 10:. PubMed
  143. Tanaka Y, et al. 2020. Sci Rep. 10:17284. PubMed
  144. Ohtsuka J, et al. 2021. iScience. Online ahead of print. PubMed
  145. Lu J, et al. 2021. Cell Death Discov. 7:165. PubMed
  146. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  147. Shen JZ, et al. 2020. Cell. 184(2):352-369.e23. PubMed
  148. Ren Y, et al. 2015. Sci Rep. 5: 18099. PubMed
  149. Kraus Z, et al. 2008. J Immunol. 181:7800. PubMed
  150. Lin W, et al. 2019. EBioMedicine. 49:133. PubMed
  151. Leclerc M, et al. 2019. Nat Commun. 10:3345. PubMed
  152. Nagatake T, et al. 2018. Int Immunol. 30:471. PubMed
  153. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  154. Xu Q, et al. 2021. Theranostics. 11:1937. PubMed
  155. Guo S, et al. 2021. Sci Rep. 11:23745. PubMed
  156. Koelwyn GJ, et al. 2020. Nat Med. 1452:26. PubMed
  157. Xu P, et al. 2020. Cancer Immunol Res. 8:1193. PubMed
  158. Karandikar SH, et al. 2019. JCI Insight. 5. PubMed
  159. Bartolacci C, et al. 2018. Cancer Immunol Res. 1.281944444. PubMed
  160. Montfort M, et al. 2004. J Immunol. 173:4084. PubMed
  161. Dong M, et al. 2022. J Immunother Cancer. 10:. PubMed
  162. Ye Q, et al. 2022. NPJ Vaccines. 7:84. PubMed
  163. Stephens WZ, et al. 2021. Cell Rep. 37:109916. PubMed
  164. Wang Y, et al. 2020. Virol Sin. 36:122. PubMed
  165. Hirata SI, et al. 2020. Allergy. 75:1939. PubMed
  166. Castiglioni P, et al. 2017. PLoS Negl Trop Dis. 10.1371/journal.pntd.0005240. PubMed
  167. Kalafati L, et al. 2020. Cell. 183:771. PubMed
  168. Roy S, et al. 2019. Front Immunol. 2.404166667. PubMed
  169. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
  170. Nagatake T, et al. 2018. J Allergy Clin Immunol. 142:470. PubMed
  171. Zhang J, et al. 2018. Nature. 553:91. PubMed
  172. Cartwright ANR, et al. 2021. Cancer Immunol Res. 9:470. PubMed
  173. Li H, et al. 2021. Front Immunol. 12:739605. PubMed
  174. Kiritsy MC, et al. 2021. Elife. 10:. PubMed
  175. Miura N, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.020. PubMed
  176. Miao W, et al. 2020. J Immunol. 1486:204. PubMed
  177. Raju S, et al. 2020. Cell Reports. 29(9):2556-2564.e3.. PubMed
  178. Mandour MF, et al. 2020. Infect Agent Cancer. 15:30. PubMed
  179. Ma Q, et al. 2022. Vaccines (Basel). 10:. PubMed
  180. Kim MY, et al. 2022. Nat Commun. 13:3296. PubMed
  181. Johnson RM, et al. 2021. Front Immunol. 11:614697. PubMed
  182. Mah-Som AY, et al. 2021. Cell Reports. 35(9):109209. PubMed
  183. Lee J, et al. 2007. Nat Immunol. 8:181. PubMed
  184. Tian D, et al. 2019. Nat Commun. 10:4246. PubMed
  185. Fang W, et al. 2021. J Exp Clin Cancer Res. 40:4. PubMed
  186. Chen L, et al. 2021. Theranostics. 11:6668. PubMed
  187. Rousso-Noori L, et al. 2021. Nat Commun. 12:3615. PubMed
  188. Wang Y, et al. 2021. Front Immunol. 11:601601. PubMed
  189. Prakash MD, et al. 2021. PLoS One. 16:e0247492. PubMed
  190. Zhang X, et al. 2020. J Cancer. 11:648. PubMed
  191. Hoechst B, et al. 2016. J Immunol. 195:1517-1523. PubMed
  192. Molgora M, et al. 2020. Cell. 182:886. PubMed
  193. Ding L et al. 2018. Cell reports. 25(11):2972-2980 . PubMed
  194. Tomaru U et al. 2019. Cell reports. 26(3):639-651 . PubMed
  195. Nakao R, et al. 2022. NPJ Vaccines. 7:153. PubMed
  196. McAusland TM, et al. 2021. Mol Ther Oncolytics. 20:306. PubMed
  197. Li H, et al. 2022. iScience. 25:104481. PubMed
  198. Schmit T, et al. 2022. Cell Rep. 38:110456. PubMed
  199. Zhang X, et al. 2021. Front Pharmacol. 12:706748. PubMed
  200. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  201. Zhao K, et al. 2021. Biomed Res Int. 7619849:2020. PubMed
  202. Charlton J, et al. 2015. PLoS One. 10:119200. PubMed
  203. Chakraborty P, et al. 2020. Cell Reports. 28(7):1879-1893.e7.. PubMed
  204. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  205. Kerdidani D, et al. 2022. J Exp Med. 219:. PubMed
  206. Zheng Y, et al. 2022. Transl Res. :. PubMed
  207. Gaylo A, et al. 2013. Transpl Immunol. 20:163. PubMed
  208. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  209. Kim YS, et al. 2018. Front Immunol. 9:1093. PubMed
  210. Wang N, et al. 2020. Front Immunol. 1.765972222. PubMed
  211. Chen PM, et al. 2022. Sci Adv. 8:eabo4271. PubMed
  212. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
  213. Yang F, et al. 2021. Nat Commun. 12:3424. PubMed
  214. Li X, et al. 2021. Front Cell Dev Biol. 9:647713. PubMed
  215. Nabekura T, et al. 2020. Immunity. 96:52. PubMed
  216. Chow AK, et al. 2021. Cellular and Molecular Gastroenterology and Hepatology. :. PubMed
  217. Tripathi D, et al. 2016. Nat Commun. 7:13896. PubMed
  218. Brenner E, et al. 2020. Nat Commun. 11:1335. PubMed
  219. Qi S, et al. 2020. Theranostics. 10:1814. PubMed
  220. Chen S, et al. 2018. Nat Commun. 9:5298. PubMed
  221. Bing Wu et al. 2018. Immunity. 49(5):886-898 . PubMed
RRID
AB_315401 (BioLegend Cat. No. 505807)
AB_315401 (BioLegend Cat. No. 505808)

Antigen Details

Structure
Cytokine; dimer; 40-80 kD (Mammalian)
Bioactivity
Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APCs
Cell Sources
CD8+ and CD4+ T cells, NK cells
Cell Targets
T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
Receptors
IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)
Cell Type
Tregs
Biology Area
Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321.
3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571.
4. Gray P, et al. 1987. Lymphokines 13:151.

Regulation
Upregulated by IL-2, FGF-basic, EGF; downregulated by 1-α-25-Dihydroxy vitamin D3, dexamethasone
Gene ID
15978 View all products for this Gene ID
UniProt
View information about IFN-gamma on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 2    Revision Date: 12/11/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account